Clinical Data ECO 2026: REDEFINE-1 demonstrates CagriSema’s improvement in body composition Pharmaceutical TechnologyData from the REDEFINE-1 trial (NCT05567796) were recently presented in Turkiye, assessing Novo Nordisk's CagriSema in adults with obesity.Metabolic & GLP-1Read full story pharminent May 13, 2026 (Last updated: May 16, 2026) Pharmaceutical Technology Data from the REDEFINE-1 trial (NCT05567796) were recently presented in Turkiye, assessing Novo Nordisk’s CagriSema in adults with obesity. Metabolic & GLP-1 Read full story Post navigation Previous: Lilly maintains weight loss leadership as Foundayo, Zepbound keep pounds off after switchingNext: Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026